Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Cash (2020 - 2026)

Xeris Biopharma Holdings filings provide 6 years of Change in Cash readings, the most recent being $19.4 million for Q4 2025.

  • On a quarterly basis, Change in Cash rose 56.95% to $19.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $39.3 million, a 866.07% increase, with the full-year FY2025 number at $39.3 million, up 866.07% from a year prior.
  • Change in Cash hit $19.4 million in Q4 2025 for Xeris Biopharma Holdings, down from $32.2 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $42.2 million in Q4 2022 to a low of -$71.0 million in Q1 2023.
  • Median Change in Cash over the past 5 years was $409000.0 (2023), compared with a mean of $3.9 million.
  • Biggest five-year swings in Change in Cash: tumbled 294.47% in 2023 and later soared 5751.85% in 2024.
  • Xeris Biopharma Holdings' Change in Cash stood at $7.8 million in 2021, then skyrocketed by 442.55% to $42.2 million in 2022, then plummeted by 49.99% to $21.1 million in 2023, then plummeted by 41.3% to $12.4 million in 2024, then surged by 56.95% to $19.4 million in 2025.
  • The last three reported values for Change in Cash were $19.4 million (Q4 2025), $32.2 million (Q3 2025), and $845000.0 (Q2 2025) per Business Quant data.